Delivery Devices Crucial To Success, Lifespan Of Asthma/COPD Meds
This article was originally published in The Gray Sheet
Executive Summary
Sales of Merck’s Singulair fell off the molecular patent cliff, but not Glaxo’s still-mighty Advair. Why? Because it has an additional patent protecting its delivery device.
You may also be interested in...
Advair Generics Likely Lucrative Product For Few That Can Clear High Bar
With release of draft bioequivalence guidance for GSK’s blockbuster asthma and COPD treatment, generics seem more likely than ever, but there may be only a select number of companies who can meet the guidance’s requirements.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.